Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.

Falcone GJ, Brouwers HB, Rosand J.

Stroke. 2012 Dec;43(12):3158-9. doi: 10.1161/STROKEAHA.112.676932. Epub 2012 Nov 15. No abstract available.

PMID:
23160886
[PubMed - indexed for MEDLINE]
Free Article
2.

Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.

Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele B.

Stroke. 2012 Dec;43(12):3189-95. doi: 10.1161/STROKEAHA.112.670604. Epub 2012 Nov 15.

PMID:
23160882
[PubMed - indexed for MEDLINE]
Free Article
3.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

PMID:
22443427
[PubMed - indexed for MEDLINE]
Free Article
4.

PAR-1 antagonists: current state of evidence.

Chatterjee S, Sharma A, Mukherjee D.

J Thromb Thrombolysis. 2013 Jan;35(1):1-9. doi: 10.1007/s11239-012-0752-4. Review.

PMID:
22644721
[PubMed - indexed for MEDLINE]
5.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators.

N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.

PMID:
22077816
[PubMed - indexed for MEDLINE]
Free Article
6.

Mechanism of action and clinical development of platelet thrombin receptor antagonists.

Ueno M, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2010 Aug;8(8):1191-200. doi: 10.1586/erc.10.49. Review.

PMID:
20670195
[PubMed - indexed for MEDLINE]
7.

Protease-activated receptor-1 antagonists: focus on SCH 530348.

Sugunaraj JP, Mehta V, Kalra A, Sukhija R, Palaniswamy C.

Am J Ther. 2012 Nov;19(6):465-9. doi: 10.1097/MJT.0b013e3181ff7c16. Review.

PMID:
21248619
[PubMed - indexed for MEDLINE]
8.
9.

Intracranial hemorrhage with Aptivu.

[No authors listed]

AIDS Patient Care STDS. 2006 Dec;20(12):889. No abstract available.

PMID:
17216876
[PubMed - indexed for MEDLINE]
10.

Platelet protease-activated receptor antagonism in cardiovascular medicine.

Wiisanen ME, Moliterno DJ.

Coron Artery Dis. 2012 Sep;23(6):375-9. doi: 10.1097/MCA.0b013e3283564946. Review.

PMID:
22781741
[PubMed - indexed for MEDLINE]
11.

Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.

Macaulay TE, Allen C, Ziada KM.

Expert Opin Pharmacother. 2010 Apr;11(6):1015-22. doi: 10.1517/14656561003720471. Review.

PMID:
20307225
[PubMed - indexed for MEDLINE]
12.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA; TRA 2°P-TIMI 50 Steering Committee Investigators.

Lancet. 2012 Oct 13;380(9850):1317-24. doi: 10.1016/S0140-6736(12)61269-0. Epub 2012 Aug 26.

PMID:
22932716
[PubMed - indexed for MEDLINE]
13.

Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.

Shinohara Y, Goto S, Doi M, Jensen P.

J Stroke Cerebrovasc Dis. 2012 May;21(4):318-24. doi: 10.1016/j.jstrokecerebrovasdis.2010.09.005. Epub 2010 Oct 14.

PMID:
20947374
[PubMed - indexed for MEDLINE]
14.

SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.

Oestreich J.

Curr Opin Investig Drugs. 2009 Sep;10(9):988-96. Review.

PMID:
19705342
[PubMed - indexed for MEDLINE]
15.

Promises of PAR-1 inhibition in acute coronary syndrome.

Leonardi S, Tricoci P, Mahaffey KW.

Curr Cardiol Rep. 2012 Feb;14(1):32-9. doi: 10.1007/s11886-011-0232-z. Review.

PMID:
22160877
[PubMed - indexed for MEDLINE]
16.

Challenges and promises of developing thrombin receptor antagonists.

Yang J, Xu K, Seiffert D.

Recent Pat Cardiovasc Drug Discov. 2010 Nov;5(3):162-70. Review.

PMID:
20874673
[PubMed - indexed for MEDLINE]
17.

PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.

Leonardi S, Becker RC.

Handb Exp Pharmacol. 2012;(210):239-60. doi: 10.1007/978-3-642-29423-5_10. Review.

PMID:
22918734
[PubMed - indexed for MEDLINE]
18.

Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.

Leonardi S, Tricoci P, Becker RC.

Adv Cardiol. 2012;47:87-99. doi: 10.1159/000338045. Epub 2012 Aug 9. Review.

PMID:
22906905
[PubMed - indexed for MEDLINE]
19.

Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease.

Van de Werf F.

Eur Heart J. 2010 Nov;31(21):2575-6. doi: 10.1093/eurheartj/ehq283. Epub 2010 Aug 30. No abstract available.

PMID:
20805114
[PubMed - indexed for MEDLINE]
Free Article
20.

Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.

Tomasello SD, Angiolillo DJ, Goto S.

Expert Opin Investig Drugs. 2010 Dec;19(12):1557-67. doi: 10.1517/13543784.2010.521741. Epub 2010 Oct 28. Review.

PMID:
20979570
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk